Quantitative MR Biomarkers for Sarcoma Treatment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01017978 |
Recruitment Status
:
Completed
First Posted
: November 23, 2009
Last Update Posted
: December 4, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Soft Tissue Tumors | Procedure: MRI Scan of soft tissue tumor | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Official Title: | Quantitative MR Biomarkers for Sarcoma Treatment |
Study Start Date : | July 2009 |
Actual Primary Completion Date : | December 2011 |
Actual Study Completion Date : | April 2012 |
Arm | Intervention/treatment |
---|---|
MRI Scan
MRI scan of soft tissue tumor
|
Procedure: MRI Scan of soft tissue tumor
MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
|
- To determine if MRI imaging can accurately determine if a sarcoma (tumor)is responding to the type of chemotherapy being used. [ Time Frame: Baseline prior to chemo ]To image and evaluate the size of the soft tissue tumor prior to chemotherapy treatment.
- MRI Scan [ Time Frame: 3 weeks post start of chemo and end of chemo ]To evaluate the size of the soft tissue tumor after start of chemotherapy to determine if the chemo is having any notable effect on tumor prior to surgery.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy proven primary bone or soft tissue tumor
- No previous treatment for this malignancy
- Will be given chemotherapy before having surgery or radiation on the tumor.
- Are able to undergo a MRI examination
- If your tumor measures at least 1/2 inch in length.
Exclusion Criteria:
- Younger than 3 yrs. of age or need general anesthesia(sedation that puts you to sleep) to have a MRI performed.
- History of Renal Failure
- Are not able to have a MRI performed for any reason such as you have a pacemaker or other implanted device that may malfunction or move because of the magnetic field inside the MRI room and scanner.
-
Have any history of an allergic reaction to gadolinium based contrast agents (a medication injected in a vein that helps create clearer MRI images.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01017978
United States, Michigan | |
University of Michigan Health System | |
Ann Arbor, Michigan, United States, 48109 |
Principal Investigator: | Gary Luker, M.D. | Universityof Michigan Health Systems |
Responsible Party: | Gary Luker M.D., Principal Investigator, University of Michigan |
ClinicalTrials.gov Identifier: | NCT01017978 History of Changes |
Other Study ID Numbers: |
HUM 00023415 |
First Posted: | November 23, 2009 Key Record Dates |
Last Update Posted: | December 4, 2015 |
Last Verified: | December 2015 |
Additional relevant MeSH terms:
Sarcoma Soft Tissue Neoplasms Neoplasms, Connective and Soft Tissue |
Neoplasms by Histologic Type Neoplasms Neoplasms by Site |